65G.F NEXTCELL PHARMA AB
- Market cap
- EUR 1.04M
- P/E
- -
- P/B
- 0.19x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 65G.F undervalued?
Graham numberThe Graham number of NEXTCELL PHARMA AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NEXTCELL PHARMA AB fundamental analysis
No fundamental analysis for NEXTCELL PHARMA AB yet.
NEXTCELL PHARMA AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NEXTCELL PHARMA AB
NextCell Pharma AB (publ), a biopharmaceutical company, engages in the research, development, and manufacture of stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank; and QVance, the first dedicated provider of quality services for developers of advanced therapies. The compa…
Full company profileNEXTCELL PHARMA AB financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 1 quarter up to Nov 30, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
NEXTCELL PHARMA AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2025 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 3.91M | 5.59M | 10.1M | 10.7M | 9.96M | 7.08M |
| Gross Profit | -14.5M | -3.13M | -885K | -4.56M | 1.63M | -635K |
| Operating Income | -24.8M | -35.0M | -41.0M | -43.2M | -40.0M | -55.6M |
| EBITDA | - | - | -39.4M | -41.0M | -36.9M | -52.6M |
| Net Income | -24.6M | -35.6M | -39.8M | -42.0M | -39.4M | -55.1M |
| EPS | -0.56 | -0.82 | -0.91 | -0.57 | -0.35 | - |
| Balance Sheet | ||||||
| Total Assets | 156M | 125M | 88.8M | 81.3M | 63.9M | - |
| Total Liabilities | 5.53M | 9.12M | 13.1M | 13.7M | 13.3M | - |
| Shareholders' Equity | 150M | 116M | 75.7M | 67.6M | 50.6M | - |
| Cash & Short-term Investments | 139M | 97.1M | 50.0M | 46.8M | 26.0M | - |
| Cash Flow | ||||||
| Operating Cash Flow | -25.6M | -33.3M | -43.8M | -37.8M | - | - |
| Capital Expenditure | 726K | 7.59M | 4.10M | 82.9K | 0.00 | 1.57M |
| Free Cash Flow | -26.3M | -40.9M | -47.9M | -37.9M | - | - |
| Ratios | ||||||
| ROE | -16.4% | -30.8% | -52.6% | -62.1% | -77.8% | - |
| ROA | -15.8% | -28.5% | -44.8% | -51.6% | -61.6% | - |
| Net Profit Margin | -627.7% | -636.2% | -393.6% | -393.4% | -395.2% | -779.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NEXTCELL PHARMA AB dividends
NEXTCELL PHARMA AB has not paid dividends in the last 5 fiscal years.
Who owns NEXTCELL PHARMA AB
- Insiders 15.32%
- Institutions 29.33%
- Public & others 55.35%
- Shares outstanding 126M
- Free float 102M
NEXTCELL PHARMA AB company profile
- Company name
- NEXTCELL PHARMA AB
- Ticker
- 65G.F
- ISIN
- SE0009723125
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 24
- Fiscal year end
- August
- Address
- Karolinska Institutet Science Park, Huddinge, Sweden, 141 57
- Phone
- 46 87 35 55 95
- Website
- nextcellpharma.com
About NEXTCELL PHARMA AB
NextCell Pharma AB (publ), a biopharmaceutical company, engages in the research, development, and manufacture of stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank; and QVance, the first dedicated provider of quality services for developers of advanced therapies. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden.
NEXTCELL PHARMA AB management
6- Dr. Mathias Svahn Ph.D.Founder & CEO · born 1976
- Mr. Eric GustafssonChief Financial Officer · born 1986
- Mr. Lindsay DaviesChief Scientific Officer & CEO of QVance · born 1979
- Mr. Edvard SmithChief Medical Officer & Director · born 1951
- Sofie Falk JanssonCEO of Cellaviva · born 1986
- Ms. Sofia SisayHead of Clinical Trials · born 1981